25B-NBOH

The following information was compiled in June 2023 and is subject to change as new research is conducted and as new information becomes available:

Description: 25B-NBOH is a novel synthetic hallucinogen bearing structural similarity to 25B-NBOMe and other “NBOH” and “NBOMe” analogues. In November 2022, 25B-NBOH was detected by our laboratory for the first time in the United States; however, this drug first emerged as early as June 2016 in Europe.

Sample Source: Los Angeles (LA) County Medical Examiner – Coroner.

Sample Appearance: Toxicology specimen – blood.

Pharmacology: Several pharmacological characterization studies involving 25B-NBOH have been published. 25B-NBOH is reported to be a potent serotonin receptor agonist, similar to 25B-NBOMe. Based on structural similarity, 25B-NBOH is expected to exhibit similar adverse effects to related “NBOH” and “NBOMe” analogues. A case report documenting hospitalizations after 25B-NBOH ingestion reported hallucinations, mydriasis, tachycardia, hypertension, and agitation, among other symptoms and effects.

Toxicology: 25B-NBOH has been detected in one toxicology case at the CFSRE.

Drug Materials: 25B-NBOH has not been identified in drug materials at the CFSRE.

Demographics / Geographics: The toxicology case originated from the state of California.

Legal Status: 25B-NBOH is not explicitly scheduled in the United States.

Class:

Hallucinogen

Appearance:

Blood

Formula:

C17H20BrNO3

MW:

366.25

[M+]:

365

[M+H]+:

366.0699

IUPAC:

2-[[2-(4-bromo-2,5-dimethoxy-phenyl)ethylamino]methyl]phenol

Report Date:

June 21, 2023